PharmAthene, Inc. [PIP] has completed its acquisition of the biodefense vaccines business unit from the United Kingdom's Avecia Biologics in a deal that bolsters its portfolio of anthrax vaccine capabilities and gives it a potential product for plague vaccine. Terms of the deal include a $10 million cash payment and additional $7 million to be paid within 18 months of the closing. Avecia will also be able to receive payments up to $23 million contingent upon the achievement of certain…
PharmAthene Acquires Avecia’s Biodefense Vaccine Unit
SHARE:
